

June 2020

CURRICULUM VITAE**BIOGRAPHICAL**

Name: Jeffrey Dale Hord, M.D. Birth Date: May 13

Citizenship: U.S.A.

Business Address: Children's Hospital Medical Center of Akron
Division of Hematology/Oncology
One Perkins Square
Akron, OH 44308

Business Phone: 330-543-8904

EDUCATION AND TRAINING**Undergraduate**

1985 University of Kentucky B.A., 1985 Chemistry, Major
Lexington, Kentucky Biology, Minor

Graduate

1985-1989 University of Kentucky M.D., 1989
College of Medicine
Lexington, Kentucky

Post Graduate

1989-1992 Children's Hospital Intern/ Pediatrics
The Ohio State University Resident
Columbus, Ohio

1992-1995 Vanderbilt University Fellow Ped. Hematology/
Nashville, Tennessee Oncology

APPOINTMENTS AND POSITIONS

1995-1999 Children's Hospital of Pittsburgh (CHP) Sick Cell Director,
Pittsburgh, Pennsylvania Hematology/
Oncology

1995-1999 University of Pittsburgh School of Medicine Assistant Professor
Pittsburgh, Pennsylvania of Pediatrics

1999-Present	Children's Hospital Medical Center of Akron (CHMCA) Akron, Ohio	Division Director, Hematology/Oncology
1999 – 2015	Children's Hospital Medical Center of Akron (CHMCA) Akron, Ohio	Director Hemostasis Thrombosis Center
1999 – 2012	Children's Hospital Medical Center of Akron (CHMCA) Akron, Ohio	Director Sickle Cell Program
1999-2007	Northeastern Ohio Universities College of Med Rootstown, Ohio	Associate Professor Pediatrics
2007-Present	Northeast Ohio Medical University Rootstown, Ohio	Professor Pediatrics
2001-Present	Pomerene Hospital Millersburg, OH	Non-provisional Courtesy Staff
2005 – 2011	Children's Hospital Medical Center of Akron (CHMCA) Akron, Ohio	Director Fellowship Program
2008-Present	Ohio University College of Osteopathic Medicine Athens, OH	Clin Assistant Prof Ped Hem/Onc
2010-2014	MetroHealth System Cleveland, OH	Affiliate Provisional Medical Staff
2013–2017	Children's Hospital Medical Center of Akron (CHMCA) Akron, Ohio	Associate Chair for Subspecialty Pediatrics

CERTIFICATION

1990	National Board of Medical Examiners
1992-2006	American Board of Pediatrics
1996-Present	ABP, Certifying Examination in Hematology/Oncology (certified, enrolled in MOC)

LICENSURE

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1989-Present	American Academy of Pediatrics, Fellow Member of Section on Hematology/Oncology
1994-Present	American Society of Hematology, Active Member
1996-Present	American Society of Pediatric Hematology/Oncology
2002-Present	Society for Pediatric Research

PROFESSIONAL ACTIVITIES

Children's Hospital of Pittsburgh-

1997-1998	Faculty Productivity Committee
1999	Oncology and Sickle Cell Summer Camps, Director

Children's Hospital Medical Center of Akron (CHMCA)-

1999-2010	Pain Management Committee
1999-Present	Cancer Committee, Chair (2000-Present)
2000-2003	End-of-Life Care Committee, Chair (2000-2002)
2000-2002	Medical Staff Executive Committee
2009-Present	
2001-2014	Children's Home Care Group Professional Advisory Committee
2001-2002	International Business Physicians Group
2001-2006	CHMCA/CHMCC Joint Management Committee
2003-2005	Department of Pediatrics Contracting Committee
2005-2007	Medical Staff Bylaws Review Committee
2006-2013	Graduate Medical Education Committee
2008-2009	Assistant Coach for the COSM Clinical Microsystems Team
2009-2015	Medical Staff Officer (Secretary/Treasurer- 2009-2010, Vice-President- 2010-2011, President-2011-2013, Past President 2013-2015)
2009-2014	Credentials Committee, Mid-Level Providers Subcommittee (2010-2013)
2009-Present	Medical Performance Improvement
2009-10, 2013-15	Medical Staff Nominating Committee
2010-Present	Bylaws Committee (Chair 2015- present)
2010-2015	Board Quality Committee
2010	Maintenance of Certification Working Group, Chair (2010)
2011	Chief Medical Officer Task Force, Co-Chair
2011	Older Patient Policy Task Force
2011	Expert Witness Policy Task Force
2011	Medical Electronic Communication Committee
2011-2012	CMIO Search Committee
2011-2017	CMIO Steering Committee
2011-2012	CMO Search Committee
2011-2013	MFM Chair Search Committee
2011-2012	Orthopedic Surgery Chair Search Committee
2012-2013	Surgery Chair Search Committee

2013-2014	Allied Health Professional Privileging Working Group, Chair
2014-2015	Department of Anesthesiology Review Committee
2014-2019	Professional Practice Evaluation
2014-2020	Akron Children's Hospital Foundation Board
2015-2016	Department of Maternal Fetal Medicine Review Committee, Chair

American Academy of Pediatrics (AAP)-

2006-2020	Section on Hematology/Oncology Executive Committee (Chair November 2012-2016)
2019-Present	Section on Hematology/Oncology Nominations Committee
2012- 2014	Leadership Team for AAP-ASPHO Alliance, Chair
2011-2020	Pediatrics In Review Editorial Board
2017-Present	Oncology Supportive Care Review Group

American Society of Hematology (ASH)-

2009-2010	Committee on Practice, ASPHO Representative
-----------	---

American Society of Pediatric Hematology/Oncology (ASPHO) -

2000-2005	Marrow Failure Workshop Co-Chair
2002-2015	Practice Management Committee (Chair, 2009-2015)
2002-2015	Certification and Continuing Education Committee
2008- 2010	Resource Sharing Subcommittee, Chair
2008-2009	Website Redesign Task Force
2011-2014	Clinical Practice Guidelines Task Force/Committee
2013-2015	Workforce Task Force, Chair
2015	ASPHO Educational Assessment Task Force
2015-2017	Workforce Writing Group (Chair)
2015-2017	Workforce Strategy Group
2016-2019	ASPHO Nominating Committee
2017-2018	ASPHO Membership Committee, Interim Chair
2018-2020	ASPHO Education Committee, Chair
2020-Present	ASPHO Board of Trustees

American Thrombosis and Hemostasis Network (ATHN)-

2010-2018	Data Quality Committee (Chair 2014-2018) which transitioned to Advisory Group status in 2018
-----------	--

Cascade Hemophilia Consortium-

2011-2016	Board of Directors
-----------	--------------------

Children's Oncology Group (COG)-

1997-2005	Supportive Care Subcommittee (Steering Committee 2002-2005)
2000-2004	Voting Body Committee
2001-2008	Adolescent and Young Adult Committee
2001-2006	End-of-Life Care Subcommittee
2003-2007	Auditor for Children's Oncology Group
2008- 2009	Order Set Working Group

Maternal Child Health Bureau-

2010-2012 Region V- East Hemophilia Advisory Group

Children's Hospital Association Childhood Cancer and Blood Disorders Network (CCBDN)

2008- 2015 Physician Faculty

Northeastern Ohio Medical University (NEOMED) -

2003-2006 Faculty Council

Ohio Department of Health-

2003- 2010 Ohio Dept of Health Newborn Screening Advisory Council

2004- 2019 BCMH Medical Advisory Council Hemophilia Subcommittee

2005-2006 Ohio Legislative Study Committee on Future Funding of BCMH

American Thrombosis and Hemostasis Network (ATHN)-

2010-2018 Data Quality Committee (Chair 2014-2018) which transitioned to
Advisory Group status in 2018

Pediatric Blood and Marrow Transplantation Consortium (PBMTC) -

2000-2003 Bone Marrow Failure Strategy Group

Solutions for Patient Safety (SPS)-

2015-Present CLABSI HAC Co-Leader

CLABSI Hem Onc Work Group Co-Leader

Other Committees-

1997-1999 Ad Hoc Advisory Committee for Birth Defects Surveillance System
Commonwealth of Pennsylvania BMC

2000 Community Hospice Outreach Task Force, Honorary MD Chair

2005 Grant reviewer for Israel Science Foundation

2006 CDC Diamond-Blackfan Medical Working Group

2008 BioInnovation Institute Clinical Trials Committee, Akron, OH

2009 Scientific and Public Health Implications of Sickle Cell Trait Meeting;
Co-sponsored by CDC, SCDA, HRSA, NIH; Atlanta, GA, Invited
participant

2014-Present US News and World Report Best Children's Hospitals Cancer Working
Group (Chair for 2015-16, 2016-17, 2017-18, 2018-19, 2019-20, 2020-21
Surveys)

EDITORIAL ACTIVITIES

Ad Hoc Reviewer for-

American Journal of Hematology (1998-2002)

Cancer (1997)
Haemophilia (2007)
Haematologica (2010)
Journal of the Pediatric Infectious Diseases Society (2018)
Journal of Pediatric Hematology/Oncology (1995, 1998, 1999, 2006, 2010, 2014, 2017)
Journal of Pediatrics (2002, 2007, 2008)
Lancet (1995)
*PAS Reviewer of Hematology Abstracts for 2004 Meeting/
Moderator for Hematology-Oncology Platform Session 5/1/04*
PAS/ASPR Reviewer of Hematology Abstracts for 2011 Meeting
Pediatric Blood & Cancer (2004, 2005, 2006, 2008, 2009, 2010, 2013, 2015, 2016,
2018, 2019)
Pediatrics (2005, 2006, 2008, 2009, 2010, 2011, 2015, 2018, 2019, 2020)
Pediatric Diabetes (2006)
Pediatric Hematology and Oncology (2009, 2014)
Pediatric Quality and Safety (2016, 2020)
The Oncologist (2007)

Editorial Board of-
Pediatrics in Review (2011-2020)

HONORS

Phi Beta Kappa
University of Kentucky Honors Program
American Cancer Society Clinical Oncology Fellow (1992-1995)
Listed as a Top Doc in Northeastern Ohio/ Best Doctors in America Database
(annually from 2004-2019)
Listed in A Guide to America's Top Pediatricians by Consumer Research Council of America-
2004-2005, 2010
Listed in A Guide to America's Top Oncologists by Consumer Research Council of America-
2009
Listed in 2005 Academic Keys Who's Who in Medical Sciences Education
Elected to Leadership Akron Class 23 (2006-07)
Listed in Castle Connolly's "America's Top Doctors for Cancer"(2008, 2009, 2011, 2012, 2013,
2014)
Listed in Castle Connolly's "America's Top Doctors" (2010, 2014, 2015)
2012 Legendary Service Award, Department of Pediatrics, Akron Children's Hospital
2014 Heart of Hudson Award, Hail to the Chefs, Hudson, Ohio

COMMUNITY SERVICE

1995-1998	Hemophilia Center of Western Pennsylvania Board of Directors
1999	Parish Council - St. Alphonsus Church, Wexford, PA
2000-2009	Bridgewater Place Homeowner's Association, President/VP/Trustee
2000- 2010	Ronald McDonald House of Akron, Board of Trustees
2012-Present	
2011	Ronald McDonald House of Akron, Honorary Director
2003-2006	Seton Catholic School Board Nominating Committee
2006-2010	Seton Athletics Association, Treasurer
2006-2012	Catholic Charities of Cleveland, Board of Directors Marketing Subcommittee
2007-2011	Akron-Canton Regional Foodbank, Volunteer
2007-2011	Haven of Rest, Volunteer
2007- 2008	Leadership Akron Alumni Association/Team XXIII
2007- 2009	Summit County Red Cross, Red Cross in Action presentations, 2008 and 2009 Breakfast of Champions presentation
2009, 2012	Chair, Hemophilia Walk to benefit the Northern Ohio Hemophilia Foundation, held 8/29/09 and 9/1/12
2015-2019	Seton Catholic School Board of Trustees
2016- Present	Children's Family Care

GRANTS

Research Advisory Committee, Children's Hospital of Pittsburgh, 1/1/96 - 6/30/99, \$46,166
 "Immunosuppression and Long -Term GM-CSF versus Immunosuppression and PIXY321 in the Treatment
 of Newly Diagnosed Children with Acquired Severe Aplastic Anemia"

Sickle Cell Disease Prevention Services, Commonwealth of PA, 7/1/97 - 8/31/99, \$488,869
 Bureau of Maternal and Child Preventive Health (RFP 96 - 07-08)

Poise Foundation, Pittsburgh, PA, 6/1/98, \$750
 Educational grant for Patient/Family Sickle Cell Conference

CytRx Corporation, 4/1/98-11/99, approx. \$25,000
 "Phase III Multicenter, Randomized Double - Blind, Placebo-Controlled Study of FLOCOR (Purified
 Poloxamer 188) in Patients with Sickle Cell Disease in Acute Vaso-occlusive Crisis "

Mayday Fund, 6/99, \$21,840
 CHP Sickle Cell Summer Camp

Children's Cancer Foundation, Pittsburgh, PA, 8/99, \$23,154
 CHP Oncology Summer Camp

Akron Children's Hospital Foundation

11/1/99 - 10/31/00 \$9,700

“High-dose Cyclophosphamide in the Treatment of Children with Acquired Severe Aplastic Anemia Refractory to Conventional Immunosuppression ”

12/11/2009 - 12/30/2012, \$4,200

“Serum Brain Natriuretic Peptide Levels and its correlation with echocardiographic measurements suggestive of pulmonary hypertension in pediatric patients

Genetech, TPA Cool Study, 2000, \$7,200

Genetics Institute, Inc./Wyeth, 4/1/00-9/02, \$76,500

“A Comparison of Immunosuppression and GM-CSF to Immunosuppression, GM - CSF, and Recombinant Human IL -11 in the Treatment of Newly Diagnosed Children with Acquired Severe Aplastic Anemia”

Cascade Hemophilia Consortium Grants - CHMCA Share of Tri-Center Grant

2000-	\$9,060
2001-	\$6,566
1/1/02-5/31/03-	\$11,938

Cascade Hemophilia Consortium Grants - Institutional Grant

1/1/02-5/31/03-	\$35,000
6/1/03-5/31/04-	\$32,000
6/1/04-5/31/05-	\$62,000
6/1/05-5/31/06	\$75,477.20
6/1/06-5/31/07	\$82,000
6/1/07-5/31/08	\$92,000
6/1/08-5/31/09	\$127,000
6/1/09-5/31/10	\$125,318
6/1/10-5/31/11	\$125,318
6/1/11-5/31/12	\$146,400
6/1/12-5/31/13	\$146,401
6/1/13-5/31/14	\$174,000
6/1/14-5/31/15	\$197,563

Maternal and Child Health Bureau (MCHB), Hemophilia Treatment Grants

6/1/00-5/31/01-	\$8,000
6/1/01-5/31/02-	\$8,000
6/1/02-5/31/03-	\$7,950
6/1/03-5/31/04-	\$9,000
6/1/04-5/31/05-	\$9,900
6/1/05-5/31/06-	\$10,800
6/1/06-5/31/07	\$10,800
6/1/07-5/31/08	\$10,800
6/1/08-5/31/09	\$20,000
6/1/09-5/31/10	\$21,875
6/1/10-5/31/11	\$18,500
6/1/11-5/31/12	\$18,500

6/1/12-5/31/13	\$18,500
6/1/13-5/31/14	\$20,000
6/1/14-5/31/15	\$20,000

Ohio Department of Health (ODH), Hemophilia

7/1/00-6/30/01-	\$143,150
7/1/01-6/30/02-	\$124,625
7/1/02-6/30/03-	\$72,883
10/1/03-6/30/04-	\$22,982 (HIPP)
7/1/04-6/30/05-	\$38,585 (HIPP)
7/1/05-6/30/06-	\$27,391 (HIPP)
7/1/06 -6/30/07	\$36,038 (HIPP)
7/1/07-6/30/08	\$35,361 (HIPP)
7/1/08 -6/30/09	\$26,212 (HIPP)
7/1/09-6/30/10	\$10,050 (HIPP)
7/1/10-6/30/11	\$ 8,114 (HIPP)

Centers for Disease Control (CDC), Regional Hemophilia Treatment Center

10/1/00-9/30/01-	\$9,614
9/30/01-9/29/02-	\$9,750
9/30/02-9/29/03-	\$9,750
9/30/03-9/29/04-	\$12,000
9/30/04-9/29/05-	\$13,140
9/30/05-9/29/06	\$14,200
9/30/06-9/29/07	\$14,200
9/30/07-9/29/08	\$14,200
9/30/08-9/29/09	\$21,875
9/30/09-9/29/10	\$20,000
9/30/10-9/29/11	\$18,500
9/30/11-9/29/12	\$18,500
9/30/12-9/29/13	\$17,500
9/30/13-9/29/14	\$17,501
9/30/14-9/29/15	\$19,501

Ohio Department of Health (ODH), Region VI Sickle Cell

7/1/00-6/30/01-	\$110,167
7/1/01-6/30/02-	\$110,167
7/1/02-6/30/03-	\$111,453
7/1/03-6/30/04-	\$111,453
7/1/04-6/30/05-	\$107,836
7/1/05-6/30/06-	\$109,198
7/1/06-6/30/07	\$109,198
7/1/07-6/30/08	\$108,346
7/1/08-6/30/09	\$108,346
7/1/09-6/30/10	\$108,346
7/1/10-6/30/11	\$108,370.52

7/1/11-6/30/12 \$104,938

7/1/12-6/30/13 \$104,000

Dorman-Baxter Foundation, Pediatric Oncology Family Support

8/2012-7/2013 \$3,300

National Childhood Cancer Foundation, NCI/COG

2000- \$47,164

2001- \$52,630

2002- \$32,700

2003- \$65,307.50

2004- \$73,956.50

The Hemophilia Alliance Foundation, 5/14/2014 – 5/31/-2014 - \$4,549

The Reinberger Foundation, Oncology Outreach Education, 2000-2002- \$50,863

Children's Family Care, Inpatient Toddler Playroom, 2002, \$50,000

Ortho-Biotech, Procrit in Children with Cancer, 2000-2005, \$20,000+

Genentech, CAPS TPA Phase IV Study, 2002-2003, \$ 2,861

Centers for Disease Control and Prevention, Grant #: 1U27DD000323-01, "Outreach to the Amish with Hemophilia": An Education Program to Promote Oral Disease Prevention and Early Intervention to Treat Bleeds, 9/30/07-12/31/09, \$320,000

American Thrombosis and Hemostasis Network, ATHN Data Management,

12/1/08-11/31/09 \$39,380

12/1/09-1/14/11 \$47,880

1/15/11-1/14/12 \$30,102

2/1/12-1/31/13 \$17,860

4/30/13-4/29/14 \$11,000

Bureau for Children with Medical Handicaps, Intra-operative Dental Interventions Among the Amish, 12/1/08-6/30/09, \$49,000

PUBLICATIONS

Refereed Articles

1. Ehmann WD, Markesberry MR, Kasarskis EJ, Vance DE, Khare SS, Hord JD, Thompson CM: Applications of neutron activation analysis to the study of age - related neurological

- diseases. *Biol Trace Element Res* 13:19-33, 1987.
2. Hord JD, Grossman NJ: Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenic purpura. *Pediatr Hematol Oncol* 10:323-327, 1993.
 3. Hord JD, Anglin D: Accidental strangulation of a toddler involving a wall light switch. *Am J Dis Child* 147:1038 - 1039, 1993.
 4. Hord JD, Grossman NJ, Whitlock JA: Immune thrombocytopenic purpura in infants. *Arch Pediatr Adolesc Med* 148:333-334, 1994.
 5. Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN: Long-term granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of severe acquired aplastic anemia. *J Pediatr Hematol Oncol* 17(2):140-144, 1995.
 6. Hord JD, Gay JC, Whitlock JA: Thrombocytopenia in neonates with trisomy 21. *Arch Pediatr Adolesc Med* 149:824-825, 1995.
 7. Whitlock JA, Wells RJ, Hord JD, Janco RL, Greer JP, Gay JC, Edwards JR, McCurley TL, Lukens JN. High dose cytosine arabinoside and etoposide: An effective regimen without anthracyclines for refractory childhood acute nonlymphocytic leukemia. *Leukemia* 11:185-189, 1997.
 8. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in hemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. *Haemophilia* 3:90 - 95, 1997.
 9. Hord JD, Whitlock JA, Gay JC, Lukens JN. Myelokathexis: Clinical features and response to hematopoietic cytokines. *J Pediatr Hematol Oncol* 19(5):443-448, 1997.
 10. Konety BR, Hord JD, Weiner ES, Schneck FX. Embryonal adenoma of the kidney associated with polycythemia and von Willebrand disease. *J Urol* 160: 2171-2174, 1998.
 11. Hord J, Byrd R, Stow L, Windsor B, Smith-Whitley K. Streptococcus Pneumoniae Sepsis and Meningitis During the Penicillin Prophylaxis Era in Children with Sickle Cell Disease. *J Pediatr Hematol Oncol*, 24(6), 2002.
 12. Hord J, Windsor B, Koehler M, Blatt J, Janosky J, Mirro J. Diminished Antibody Response to Hepatitis B Immunization in Children with Sickle Cell Disease. *J Pediatr Hematol Oncol*, 24(7), 2002.
 13. Hummel T, Hord J. Favorable Response to Soft Tissue Sarcoma Therapy in an Adolescent with Embryonal Renal Sarcoma. *Pediatr Blood Cancer* 43:70 - 72, 2004.
 14. Cockrell E, Gorman J, Hord J. Endogenous IL-11 Levels in Newly Diagnosed Children

- with Acquired Severe Aplastic Anemia. *Cytokine* 28(2):55-58, 2004.
15. Scott E, Haider A, Hord J. Growth Hormone Therapy for Short Stature in Diamond-Blackfan Anemia. *Pediatr Blood Cancer* 43:542-544, 2004.
 16. Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI. Hemoglobin Response and Improvements in Quality of Life in Anemic Children with Cancer Receiving Myelosuppressive Chemotherapy. *J Support Oncol* 3(6 suppl 4):10 - 1, 2005.
 17. Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff W. Once-Weekly Treatment with Intravenous Epoetin Alfa in Children with Cancer Receiving Myelosuppressive Chemotherapy: a Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic Endpoints, and Safety. *J Clin Oncol* 24:3583-3589, 2006.
 18. Hord JD, Rehman W, Hannon P, Anderson-Shaw L, Schmidt ML. Do Parents Have the Right to Refuse Standard Treatment for Their Child with Favorable Prognosis Cancer? B Ethical and Legal Concerns. *J Clin Oncol* 24:5454-5456, 2006.
 19. Audino A, Blatt J, Carcamo B, Castaneda V, Dinndorf P, Wang W, Whitlock J, Hord J. High-Dose Cyclophosphamide Treatment for Refractory Severe Aplastic Anemia in Children. *Pediatr Blood Cancer* 54:269-272, 2010.
 20. Kempton CL, Allen G, Hord J, et al. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. *Am J Hematol* 87(9):933-6, 2012.
 21. Gaur AH, Bundy DG, Gao C, Werner EJ, Billett AL, Hord JD, Siegel JD, Dickens D, Winkle C, Miller MR and Children's Hospital Association Hematology-Oncology Quality Transformation Collaborative Project. Surveillance of Hospital-Acquired Central Line-Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients: Lessons Learned, Challenges Ahead. *Infection Control and Hospital Epidemiology*, Vol. 34, No. 3, 316-320, 2013.
 22. Anderst JD, Carpenter SL, Abshire TC, Hord J, et al. Evaluation of bleeding disorders in suspected child abuse. *Pediatrics* 131(4): e1314-22, 2013.
 23. Hord JD, Lawlor J, Werner E, Billett AL, Bundy DG, Winkle C, Gaur AH. Central Line-Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients with Different Types of Central Lines. *Pediatric Blood and Cancer*, 2016;63:1603-1607.
 24. Gaur AH, Bundy DG, Werner E, Hord J, Miller MR, Tang L, Lawlor J, Billett AL. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients. *Infection Control and Hospital Epidemiology*, 2017 Apr 12:1-7. doi: 10.1017/ice.2017.57. [Epub ahead of print]
 25. Hord J, Shah M, Matthews D, Hilden J, Badawy SM, Salsberg E, Leavy P, on behalf of the

American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce. Current State of the Pediatric Hematology Oncology Workforce: Results of the American Society of Pediatric Hematology Oncology Workforce Analysis. *Pediatr Blood Cancer*. 2017;00:e26780. <https://doi.org/10.1002/pbc.26780>

26. Leavey, P.J., Hilden, J.M., Matthews, D., Dandoy, C., Badaway, S., Shah, M., Wayne, A. and Hord J., on behalf of the American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce. Pediatric Hematology/Oncology Workforce Assessment: A report from the American Society of Pediatric Hematology/Oncology. *Pediatr Blood Cancer*. 2017;00:e26765. <https://doi.org/10.1002/pbc.26765>
27. Dandoy C, Kelley T, Gaur AH, Nagarajan R, Demmel K, Alonso PB, Guinipero T, Savelli S, Hakim H, Owings A, Myers K, Aquino V, Oldridge C, Rae ML, Schjodt K, Kilcrease T, Scurlock M, Marshburn AM, Hill M, Langevin M, Lee J, Cooksey R, Mian A, Eckles S, Ferrell J, El-Bietar J, Nelson A, Turpin B, Huang FS, Lawlor J, Esporas M, Lane A, Hord J, Billett A. Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. *Pediatr Blood Cancer*, 2019; e27978. [<https://doi.org/a0.1002/pbc.27978>]
28. Hakim H, Billett A, Xu J, Tang L, Richardson T, Winkle C, Werner E, Hord J, Bundy D, Gaur A. Mucosal Barrier Injury-Associated Bloodstream Infections in Pediatric Oncology Patients. *Pediatric Blood and Cancer*, 2020, <https://doi.org/10.1002/pbc.28234>.

Chapters and Reviews

1. Hord JD, Greer JP: Epidemiology of cancer in children. In: Parris WCV (ed), Cancer Pain Management. New York: Butterworth and Heinemann, 1996.
2. Hord JD, Lukens JN: Hematology and anemias unique to infants and children. In: Lee GR, Foerster J, Greer J, Lukens J, Rodgers G, Paraskevas F (ed), Wintrobe's Clinical Hematology. Baltimore: Williams and Wilkins, 1998.
3. Hord JD. Anemia and coagulation disorders in adolescents. *Adol Med* 10(3):359-367, 1999.
4. Hord JD. Treatment Strategies in Pediatrics (for handheld devices). Contributor and specialty editor for Hematologic Disorders. Philadelphia: PocketMedicine.com, Inc., 2002.
5. Hord JD. Hematology and Oncology. In: Holland C, Brown R (ed), Adolescent Medicine Secrets. Philadelphia: Hanley & Belfus, 2002.
6. Hord JD. Aplastic Anemia. In: Rakel RE, Bope ET (ed), Conn's Current Therapy, 55th Edition. Philadelphia: W.B. Saunders Co., 2003.
7. Hord JD. Acquired Pancytopenias. In: Behrman R, Kliegman R, Jenson H (ed), Nelson Textbook of Pediatrics, 17th Edition. Philadelphia: W.B. Saunders Co, 2003.

8. Hord JD, Cartwright J. Hematopoietic Growth Factors in Children with Cancer. In: Altman A (ed), Supportive Care of Children with Cancer, 3rd Edition. Baltimore: The Johns Hopkins University Press, 2004.
9. Hord JD. Contributor and specialty editor for Hematologic Disorders. In: Powell K(ed), Treatment Strategies in Pediatrics, 2nd Edition (for handheld devices). Philadelphia: PocketMedicine.com, Inc., 2006.
10. Hord JD. Acquired Pancytopenias. In: Behrman R, Kliegman R, Jenson H (ed), Nelson Textbook of Pediatrics, 18th Edition. Philadelphia: Elsevier, 2007.
11. Hord JD, Rice SG. NCAA recommends screening all college athletes for sickle cell trait. *AAP News* 30;1;2009.
12. Hord JD. Acquired Pancytopenias. In: Behrman R, Kliegman R, Jenson H (ed), Nelson Textbook of Pediatrics, 19th Edition. Philadelphia: Elsevier, 2011.
13. Hord J. “Hematopoietic Growth Factors” in Supportive Care in Pediatric Oncology, 1st edition. Feusner and Hastings, editors. New York: Springer, 2015
14. Hord JD. Acquired Pancytopenias. In: Behrman R, Kliegman R, Jenson H (ed), Nelson Textbook of Pediatrics, 20th Edition. Philadelphia: Elsevier, 2015.
15. Fargo J and Hord J. Acquired Pancytopenias. In: Behrman R, Kliegman R, Jenson H (ed), Nelson Textbook of Pediatrics, 21st Edition. Philadelphia: Elsevier, (submitted January 2017)
16. Hord JD, Hays JA, Chu R. Careers in Quality Improvement and Patient Safety. In “Improving Patient Safety and Quality in the Pediatric Hematology/Oncology and Hematopoietic Stem Cell Transplant Practice (Dandoy C, Hilden J, Mueller B, Billet A). Spring, New York, NY. (Published 2017)

Letters

1. Hord JD, Janco RL. Chemotherapy for unresectable pancreaticoblastoma. *Med Pediatr Oncol* 26(6):432-433,1996.
2. Hord JD. Compensation Survey Summary. ASPHO President’s Newsletter. Issue 3. August 2006.
3. Razzouk BI, Hord JD. “In reply” to letter to the editor following 2006 JCO Epoietin manuscript. *J Clin Oncol*, 25(7): 919-920, 2007.
4. Berntorp E, Shapiro AD, Waters J, et al. The International Factor IX Network Survey. *Haemophilia* 18, e60-e62, 2012.

5. Hord J. The Patient-Centered Medical Home Is Not Always the Primary Care Provider's Office. **AAP Publications** Blog. <http://www.aappublications.org/news/2018/05/04/the-patient-centered-medical-home-is-not-always-the-primary-care-providers-office-pediatrics-in-review-5-4-18>
6. Hord J. The Many Levels of Personalized Pediatric Oncology Treatment. **AAP Publications** Blog. <http://www.aappublications.org/news/2018/10/25/the-many-levels-of-personalized-pediatric-oncology-treatment-pediatrics-in-review-10-25-18>
7. Terao M, Hord J. Tips for Graduating Pediatric Hematology/Oncology Fellows Searching for their First Job. AAP Section on Hematology/Oncology Newsletter, Spring 2020.

Abstracts

1. Hord JD, Grossman NJ: Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenic purpura. *Proceedings of the American Society of Pediatric Hematology/Oncology* 1:19, 1992.
2. Hord JD, Grossman NJ, Whitlock JA, Gay JC, Janco RL, Lukens JN, Edwards JR, Greer JP: Immune thrombocytopenic purpura in infants. *Pediatr Res* 33(4):140A (Part II), 1993.
3. Whitlock JA, Greer JP, Hord JD, Janco RL, Gay JC, Edwards JR, Lukens JN: Extended high-dose ara-C/VP-16 is an effective regimen with acceptable toxicities for refractory acute leukemia in children. *Pediatr Res* 33(4):149A (Part II), 1993.
4. Hord JD, Gay, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN: Long-term granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. *Blood* 84 (10, Suppl 1):9A, 1994.
5. Hord JD, Greer JP: Regression of a venous malformation during treatment with interferon alpha-2a. *Blood* 84(10, Suppl 1):677A, 1994.
6. Setty SN, Bickman P, Hord J, Schmidt ML. Cisplatin (CDDP) substitution for carboplatin (CBDCA): An easily occurring but preventable fatal error. *Proceedings of the American Society of Clinical Oncology*, Vol. 15, 1996.
7. Hord J, Saglamer L, Bigbee W, Grant S. Increased somatic mutation frequency in erythrocytes from children with homozygous hemoglobin S disease and reticulocytosis. *Blood* 90(10,Suppl 1):27b, 1997.
8. Hord J, Lukens J, Smith-Whitley K, Martin M, McKenzie SE. Follow - up of thirteen children with severe aplastic anemia treated with anti - thymocyte globulin, cyclosporine, and GM-CSF. *Blood* 90(10, Suppl 1):439a, 1997.
9. Hord J, Smith-Whitley K, Byrd R, Stowe L, Windsor B. Streptococcus pneumoniae sepsis

- and meningitis in children with sickle cell disease in the penicillin prophylaxis era. *Blood* 92(10, Suppl 1): 526a, 1998.
10. Hord J, Wang W, Rogers ZR, Smith-Whitley K, McKenzie S, Reaman G, Lukens J, and the Pediatric Aplastic Anemia Cooperative Trial Group. Immunosuppression and GM - CSF or PIXY321 are effective in the treatment of children with acquired severe aplastic anemia. *Blood* 92(10, Suppl 1):157a, 1998.
 11. Young G, Manco-Johnson M, Nuss, R, Sandon-Kleiboer, Axtell R, Gill J, Driscoll M, DiMichelee D, Tarantino M, Abshire T, Lerner N, Hord J, Nugent D. Thrombotic Manifestations of the Prothrombin G20210A Mutation in Children. *Blood* (Suppl):648a, Nov 2000.
 12. Luccy BM, Saglamer L, Bigbee WL, Hord JD, Grant SG. Somatic Mutational Evidence for Tissue-Specific Premature Aging in the Bone Marrow of Patients with Sickle Cell Hemoglobinopathy. *American Journal of Human Genetics* 67 (suppl 2): 77, 2000.
 13. Hord J, Kakish J, Miller E, Dery A. Characteristics of a Large Factor IX Deficient Pediatric Population. *HEMAware* 6(6):6, 2001.
 14. Hord J, Blatt J, Rogers Z, Dinndorf P, Alvarado C, and PAACT Group. Unacceptable Toxicity Associated with Recombinant Human IL-11 (rhIL-11) Therapy in Children with Severe Aplastic Anemia. *Blood* 100(11, part 2):20b, 2002.
 15. Kasunick L, Hord J, Sapatnekar S. Vascular access with the Arrow A2 dual port for pediatric erythrocytapheresis. *J Clin Apheresis* 17(3):2002.
 16. Hord J, Shaw C, Kasunick L, Sapatnekar S. Erythrocytapheresis with Indwelling Central Venous Catheters in Children with Sickle Cell Disease on a Chronic Transfusion Program. *Pediatr Res* 53(4, part 2);279A, 2003.
 17. Cockrell E, Hord J, Gorman J, et al. Endogenous IL-11 Levels in Newly Diagnosed Children with Acquired Severe Aplastic Anemia. *Pediatr Res* 53(4, part 2);294A, 2003.
 18. Scott E, Haider A, Hord J. Growth Hormone for Short Stature in a Child with Diamond Blackfan Anemia. *Pediatr Res* 53(4, part 2);299A, 2003.
 19. Fleck D, Schmidt M, Weitzman S, Dubansky S, Hord J. Parental Refusal of Standard Chemotherapy for Young Children with Favorable Prognosis Leukemia. *Pediatr Res* 53(4, part 2);301A, 2003.
 20. Saxena K, Gross T, Zhou B, Kraut E, Shapiro A, Hord J, Ruymann F, and Yu C. Immunogenetics of Hemophilia Inhibitors: A Multicenter Study. *Blood* 102(11, part 1);800A, 2003.
 21. Saxena K, Gross T, Zhou B, Kraut E, Shapiro A, Hord J, Ruymann F, and Yu C.

Immunogenetics of Hemophilia Inhibitors: A Multicenter Study. *Pediatr Res* 55(4, part 2); 286A, 2004.

22. Razzouk B, Hockenberry M, Hinds P, Feusner J, Rackoff W, Hord J. A double-blind, placebo-controlled trial of intravenously administered once weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. *ProcASCO* 23:abstract 8527, 2004.
23. Razzouk BI, Hockenberry M, Hinds P, Feusner J, Rackoff W, Hord J. Influence of hemoglobin response to epoetin alfa on quality-of-life in anemic children with cancer receiving myelosuppressive chemotherapy. *Blood*,104 (11, part 1); 609a, 2004.
24. Hord JD, Whitlock JA, Carcamo B, Pais R, Blatt J, Dinndorf P, Wang W. High-dose cyclophosphamide in the treatment of children with acquired severe aplastic anemia refractory to conventional immunosuppression. *Blood*, 104 (11, part 2); 14b, 2004.
25. Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Razzouk BI. Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (2005 ONS Conference)
26. Audino A*, Shaw C, Hord J. Erythrocytapheresis Is Effective in Reducing Serum Ferritin among Children with Sickle Cell Disease, but Impact on Total Body Iron is Uncertain. *Pediatr Blood Cancer* 52(6):705, 2009.
27. Cockrell E*, Vilella A, Hord J. Report of a Rare Gene Mutation in a Patient with non-Classical Diamond-Blackfan Anemia. *Pediatr Blood Cancer* 52(6):706, 2009.
28. Li X, Kuerbitz S, Hord J, Agamanolis D, Li A, Ali D, Salvator A, Smith M, Haydu G.. Clinical Features of Pleomorphic Xanthoastrocytoma. *Pediatr Blood Cancer* 54(6): 846, 2010.
29. Chen C, Ullman M, Hord J, Kulkarni R, Konkle B, Baker J, Riske B, Koerper M, Wu J, Lou M, Nichol M. Characteristics Associated with Annual Bleeding Frequency Among Hemophilia Patients in the United States. *Value In Health* 18:A682, 2015.

Recognized Contributor to-

1. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle Myosin Heavy Chain IIA Mutations Define a Spectrum of Autosomal Dominant Macrothrombocytopenias: May-Hegglin Anomaly and Fechtner, Sebastian, Epstein, and Alport - Like Syndromes. *Am J Hum Genet* 69: 1033-1045, 2001.
2. Young G, Manco-Johnson M, Gill JC, DiMichele DM, Tarantino M, Abshire T, Nugent D. Clinical Manifestations of the Prothrombin G20210A Mutation in Children: A Pediatric Coagulation Consortium Study. *J Thrombosis Hemostasis* 1:958-962, 2002.
3. Semba CP, Deitcher SR, Li X, et al. Treatment of Occluded Central Venous Catheters with Alteplase: Results in 1,064 Patients. *J Vasc Interv Radiol* 13:1199-1206, 2002.

4. Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. *Blood* 100:427-434, 2002.
5. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of Radiotherapy for High-Risk Neuroblastoma: A Children's Cancer Group Study. *Int J Radiation Oncology Biol Phys* 56(1):28-39, 2003.
6. Blanchette VS, McCready M, Achonu C, et al. A survey of factor prophylaxis in boys with haemophilia followed in North America haemophilia treatment centres. *Haemophilia* 9(suppl 1):19-26, 2003.
7. Adkins ES, Sawin R, Gerbing RB, et al. Efficacy of Complete Resection for High-Risk Neuroblastoma: A Children's Cancer Group Study. *J Pediatr Surg* 39:931-936, 2004.
8. Lones MA, Sanger WG, LeBeau M, et al. Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphoma of Children and Adolescents. *J Pediatr Hematol Oncol*, 26(3):169-178, 2004.
9. Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. *Blood* 103(10):3655-3661, 2004.
10. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, and HTRS Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. *Haemophilia* 11:100-106, 2005.
11. Fung EB, Harmatz PR, Lee PDK, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassemia versus sickle cell disease. *Br J Hematol* 135: 574-582, 2006.
12. Fung EB, Harmatz PR, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. *Am J Hematol* 82:255-265, 2007.
13. Fung E, Harmatz PR, Milet M, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. *Bone* 43(1):162-168, 2008.
14. Fung EB, Harmatz PR, Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. *Transfusion* 2008 May 29 (Epub ahead of print).

15. American Academy of Pediatrics Section on Hematology/Oncology and Children's Oncology Group. Long-Term Follow-Up Care for Pediatric Cancer Survivors. *Pediatrics* 123(3): 906-915, 2009.
16. Flood VH, Schlauderaff ACV, Haberichter SL, et al. Crucial role for the VWF A1 domain in binding to type IV collagen. *Blood* 125(14): 2297-2304, 2015.

SCIENTIFIC PRESENTATIONS

Oral Presentations

1. Ehmann WD*, Markesberry MR, Kasarskis EJ, Vance DE, Khare SS, Hord JD, Thompson CM: Applications of neutron activation analysis to the study of age-related neurological diseases. Second International Symposium on the Biology and Toxicology of Metals Using Analytical Methods. Brookhaven National Laboratory, Long Island, New York, 1985.
2. Hord JD*, Grossman NJ. Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenic purpura. Children's Hospital Research Forum, Columbus, OH. June, 1992.
3. Hord JD*, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN: Long-term granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of severe acquired aplastic anemia. Presented at the 12th Annual Vanderbilt University Medical Center Research Forum, 1994.
4. Hord JD*. GM-CSF and PIXY321 in the treatment of children with severe acquired aplastic anemia. Seminar sponsored by Immunex Corporation held in conjunction with the 1996 meeting of the American Society of Pediatric Hematology/Oncology. October, 1996.
5. Hord JD*, Smith-Whitley K, Byrd R, Stowe L, Windsor B. Severe streptococcus pneumoniae infections in children ages 5 years and older with sickle cell disease. 1997 National Sickle Cell Disease Program, Washington, D.C. September 1997.
6. Kasunick L*, Hord J, Sapatnekar S. Vascular access with the Arrow A2 dual port for pediatric erythrocytapheresis. 2002 American Society for Apheresis Mtg. June 2002.
7. Audino A*, Hord J. Influence of disease type, gender, age, and chronic transfusion on the incidence of pulmonary hypertension among children with sickle cell disease. SCDA 36th Annual Convention, New Orleans, LA, September 2008.
8. Hartland M*, Boehlefeld I, Wright E, Hord J. Oral Health Education in One Amish Parochial School District. National Conference on Blood Disorders in Public Health. Atlanta, GA. March 2010.

9. Lewis L*, Hord J. Our Program's Approach to Sickle Cell Trait and Athletes. Sickle Cell Disease Association of America 38th Annual Convention. Washington, DC. September 2010.
15. Hord J. Results of the 2010 ASPHO Physician Compensation and Productivity Survey. 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
16. Billet A, Werner E, Hord J, et al .Reducing Central Line-Associated Bloodstream Infections (CLABSIs) among Pediatric Hematology-Oncology (PHO) Inpatients: Results from the Children's Hospital Association National Collaborative. ASPHO Annual Meeting, April 2013 (platform presentation by Dr. Billet)
17. Hord J. Ongoing Professional Practice Evaluations in Pediatric Hematology Oncology. Practice Management Workshop, ASPHO Annual Meeting, April 2013.
13. Niu X, Lou M, Poon JL, Kulkarni R, Riske B, Ullman M, Baker J, Parish K, Hord J, Curtis R, Nichol MB. Association Between Health Status of Person With Hemophilia B and Consumption of Factor IX Concentrate- Hemophilia Utilization Group Study Part Vb. World Federation of Hemophilia 2014 World Congress, Melbourne, Australia, May 2014.

Poster Presentations

1. Hord JD*, Grossman NJ. Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenia purpura. Amer Soc Ped Hem/Onc. OCT 1992.
2. Hord JD*, Grossman NJ, Whitlock JA, Gay JC, Janco RL, Lukens JN, Edwards JR, Greer JP. Immune thrombocytopenic purpura in infants. Vanderbilt University Medical Center Research Forum. April, 1993.
3. Hord JD*, Grossman NJ, Whitlock JA, Gay JC, Janco RL, Lukens JN, Edwards JR, Greer JP. Immune thrombocytopenic purpura in infants. Society for Pediatric Research. May, 1993.
4. Whitlock JA*, Greer JP, Hord JD, Janco RL, Gay JC, Edwards JR, Lukens JN. Extended high-dose ARA-C/VP-16 is an effective regimen with acceptable toxicities of refractory acute leukemia in children. Society for Pediatric Research. May, 1993.
5. Hord JD*, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Luken JN. Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. American Society of Hematology. December, 1994.
6. Hord J*, Lukens J, Smith-Whitley K, Martin M, McKenzie SE. Follow - up of thirteen children with severe aplastic anemia treated with anti-thymocyte globulin, cyclosporine,

and GM-CSF. American Society of Hematology. December 1997.

7. Hord J*, Smith-Whitley K, Byrd R, Stowe L, Windsor B. Streptococcus pneumoniae sepsis and meningitis in children with sickle cell disease in the penicillin prophylaxis era. American Society of Hematology, December 1998.
8. Hord J*, Wang W, Rogers ZR, Smith-Whitley K, McKenzie S, Reaman G, Lukens J, and the Pediatric Aplastic Anemia Cooperative Trial Group. Immunosuppression and GM - CSF or PIXY321 are effective in the treatment of children with acquired severe aplastic anemia. American Society of Hematology, December 1998.
9. Hord J*, Windsor B, M Koehler, J Blatt, C Phebus, J Mirro. Poor antibody response to hepatitis B immunization in children with sickle cell disease. National Sickle Cell Disease Program, March 1999.
10. Luccy BM*, Saglamer L, Bigbee WL, Hord JD, Grant SG. Somatic Mutational Evidence for Tissue-Specific Premature Aging in the Bone Marrow of Patients with Sickle Cell Hemoglobinopathy. American Society of Human Genetics, October 2000.
11. Hord J*, Kakish J, Miller E, Dery A. Characteristics of a Large Factor IX Deficient Pediatric Population. 53rd Annual Meeting of the National Hemophilia Foundation, November 2001.
12. Hord J*, Shaw C, Kasunick L, Sapatnekar S. Erythrocytapheresis with Indwelling Central Venous Catheters in Children with Sickle Cell Disease on a Chronic Transfusion Program. American Society of Pediatric Hematology/Oncology Annual Meeting, May 2003.
13. Saxena K*, Gross T, Zhou B, Kraut E, Shapiro A, Hord J, Ruymann F, and Yu C. Immunogenetics of Hemophilia Inhibitors: A Multicenter Study. American Society of Hematology 45th Annual Meeting, December 2003.
14. Saxena K*, Gross T, Zhou B, Kraut E, Shapiro A, Hord J, Ruymann F, and Yu C. Immunogenetics of Hemophilia Inhibitors: A Multicenter Study. American Society of Pediatric Hematology/Oncology/ PAS Annual Meeting, May 2004.
15. Razzouk B*, Hockenberry M, Hinds P, Feusner J, Rackoff W, Hord J. Double-blind, placebo-controlled trial of intravenous epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. 2004 ASCO Meeting, June 2004.
16. Hord JD, Broderick E*, Androulakakis V, and Shaw C. No relationship found between the frequency of vaso-occlusive painful crises and weather in Akron, OH. Annual Convention of the Sickle Cell Disease Association of America, Atlanta, GA, Sept 2004.
17. Razzouk BI*, Hockenberry M, Hinds P, Feusner J, Rackoff W, Hord J. Influence of hemoglobin response to epoetin alfa on quality-of-life in anemic children with cancer receiving myelosuppressive chemotherapy. American Society of Hematology 46th Annual Meeting, December 2004.

18. Hinds P*, Hockenberry M, Feusner J, Hord J, Rackoff W, Razzouk B. Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. Oncology Nursing Society Annual Meeting, 2005.
19. Hartland M*, Boehlefeld I, Hord J. Improving the Oral Health of an Amish Population with Hemophilia. Oral Health in the 21st Century, Boston, MA, October 10, 2008.
20. Ragni M, Nalesnik M, Qin L, Moore C. Cytokines and Liver Fibrosis in HIV/HCV Co-Infection: The HHH Hemophilia Cohort Study. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 2009 (acknowledged as **contributor**).
21. Audino A*, Shaw C, Hord J. Erythrocytapheresis Is Effective in Reducing Serum Ferritin among Children with Sickle Cell Disease, but Impact on Total Body Iron is Uncertain. . 22nd Annual Meeting of the American Society of Pediatric Hematology/Oncology, San Diego, CA, April 23, 2009.
22. Cockrell E*, Villela A, Hord J. Report of a Rare Gene Mutation in a Patient with non-Classical Diamond-Blackfan Anemia. 22nd Annual Meeting of the American Society of Pediatric Hematology/Oncology, San Diego, CA, April 23, 2009.
23. Oldenburg J, Luu H, Spotts G, et al. ADVATE rAHF-PFM Post-authorization Safety Surveillance (PASS): Final EU and US Safety and Efficacy Results. 2009 ISTH Congress, Boston, July 15, 2009 (acknowledged as **contributor**).
24. Griggs J*, Lewis L, Hord J. Outreach Education Strategy for Sickle Cell Disease and Sickle Cell Trait. Annual Convention of the Sickle Cell Disease Association of America, Orlando, FL, Sept 2009
25. Shaw C*, Hord J, Neitz S, Luzader J. Screening Pediatric Sickle Cell Disease Patients for Potential HLA-Matched HSC Transplant. Annual Convention of the Sickle Cell Disease Association of America, Orlando, FL, Sept 2009
26. Hartland M*, Wright E, Simmons G, Hord J. Improving the Oral Health of Amish and Mennonite Patients Living with Bleeding Disorders through Patient and Community Education. Annual Meeting of the National Hemophilia Foundation, San Francisco, CA, October 2009.
27. Boehlefeld I*, Hartland M, Wright E, Hord J. Amish Utilization of Home Infusion Training and Treatment Logs to Improve Health Outcomes. National Conference on Blood Disorders, Atlanta, GA, March 2010.
28. Hartland M*, Boehlefeld I, Wright E, Hord J. Addressing Oral Health in a Population of Amish Patients Living with Bleeding Disorders. National Conference on Blood Disorders, Atlanta, GA, March 2010.

29. Hartland M*, Boehlefeld I, Hord J. An Amish Community's Effort to Improve the Health of People Living with Bleeding Disorders. National Conference on Blood Disorders, Atlanta, GA. March 2010.
30. Li X, Kuerbitz S, Hord J*, Agamanolis D, Li A, Ali D, Salvator A, Smith M, Haydu G.. Clinical Features of Pleomorphic Xanthoastrocytoma. 23rd Annual Meeting of the American Society of Pediatric Hematology/Oncology, Montreal, Quebec, Canada. April 2010.
31. Bhatia R* Hord J. High-grade Undifferentiated Myxoid Sarcoma- A Rare Presentation. Regional American College of Surgeons Meeting, Columbus, OH. Fall 2010.
32. Saeed H*, Hord J. The Dilemma of Cold Agglutinins in Pediatric Cardiac Surgery Patients Requiring Hypothermia: Our Experience with Four Patients. 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
33. Watts A*, Wright E, Mitchell J, Friebert S, Hord J. Childhood Cancer In A Large Anabaptist Population. 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
34. Hord J*, Lawlor J, on behalf of the NACHRI Hem/Onc Quality Collaborative. Epidemiology And Incidence Of Central-Line Associated Blood Stream Infections (CLABSI) Among Hospitalized Pediatric Hematology/Oncology Patients. 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
35. Hord J* and the ASPHO Practice Committee. Gender Gap In Physician Compensation In Pediatric Hematology/Oncology. 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
39. Werner E, Billett A, Hord J. Successful Implementation of a Multicenter Pediatric Hematology/Oncology Central Line Associated Blood Stream Infection Collaborative. 25th Annual Meeting of the American Society of Pediatric Hematology/Oncology, New Orleans, LA. May 2012.
40. Billett AL, Gaur AH, Werner E, Winkle C, Hord J, Brown R, Bundy D, Miller M. Moving Prevention Of Central Line Associated Bloodstream Infection Efforts Beyond The Hospital Walls - A Multicenter Pediatric Hematology/Oncology Collaborative. Annual Meeting of the American Society of Clinical Oncology, November 2012.
41. Hord J. Professional Fees only constitute the tip of the iceberg when it comes to Pediatric Hematology/Oncology CLINCIAL Revenue. ASPHO Annual Meeting, April 2013
42. Saeed H, Hord J. HIGH DOSE METHOTREXATE (HD-MTX) IN TREATMENT OF EXTRA-RENAL RHABDOID TUMOR (ERRT) WITH DIFFUSE LEPTOMENINGEAL SPREAD. ASPHO Annual Meeting, April 2013

43. Pettee D, Hord J. AML1 AMPLIFICATION AND OUTCOMES IN 8 PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE SERIES AND REVIEW. ASPHO Annual Meeting, April 2013
44. Niu X, Poon JL, Riske B, Baker J, Lou M, Kulkarni R, Hord J*, Konkle BA, Ullman M, Nichol MB,. Healthcare Utilization in Persons with Hemophilia B – Hemophilia Utilization Group Study Vb (HUGS Vb). Hemostasis and Thrombosis Research Society Annual Meeting, Charlotte, NC. April 2013.
45. Niu X, Poon JL, Lou M, Ullman M, Koerper M, Baker J, Hord J*, Konkle BA, Riske B, Buranahirum C, Gwadry-Sridhar F, Curtis RG, Kulkarni R, Soni A, Nichol MB. Burden of Bleeding Episodes among Persons with Hemophilia B. (HUGS VB) National Hemophilia Foundation 65th Annual Meeting, Anaheim , CA. October 2013.
46. Hord J*, Lawlor J, CHA Hem Onc QTN. Organisms Responsible for Central Line-Associated Bloodstream Infections in Hospitalized and Ambulatory Pediatric Hematology/Oncology Patients. 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Chicago, IL. May 2014.
47. Hord J*, Lawlor J, CHA Hem Onc QTN. Central Line-Associated Bloodstream Infection Rates In Hospitalized and Ambulatory Pediatric Hematology/Oncology Patients by Central Line Type. 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Chicago, IL. May 2014.
48. Niu X, Lou M, Poon JL, Kulkarni R, Riske B, Ullman M, Baker J, Parish K, Hord J*, Curtis RG, Wu J, Koerper M, Nichol MB. Association Between Health Status and Consumption of Factor IX Concentrate among Persons with Hemophilia B – Hemophilia Utilization Group Study Part V (HUGS V). World Federation of Hemophilia 2014 World Congress, Melbourne, Australia, May 2014.
49. Niu X, Lou M, Baker J, Poon JL, Konkle BA, Ullman M, Riske B, Hord J*, Kulkarni R, Curtis RG, Koerper M, Wu J, Nichol MB. Measuring work or school absence associated with administration of factor concentrate in children with hemophilia in the United States – Hemophilia Utilization Group Study Part V (HUGS V). World Federation of Hemophilia 2014 World Congress, Melbourne, Australia, May 2014.
50. Christina X. Chen, Judith R. Baker, Barbara A. Konkle, Megan Ullman, Roshni Kulkarni, Jeffrey Hord, Mimi Lou, Michael B. Nichol. BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS. International Society of Thrombosis and Hemostasis, Toronto CA, June 2015.
51. Chen C, Konkle B, Hord J, Ullman M, Soni A, Niu X, Baker J, Kulkarni R, Lou M, Wu J, Nichol M. Associations Between Annual Bleeding Episodes and Financial Burden of Illness Among Persons with Hemophilia A and Hemophilia B in the United States. National Hemophilia Foundation Annual Meeting, Dallas, Texas, August 2015.

52. Buranahirun C, Curtis R, Ullman M, Norton K, Baker J, Riske B, Niu X, Lou M, Hord J, Kulkarni R, Chen C, Soni A, Nichol M. Relative Health Status of Young Adults in the Hemophilia Utilization Group Studies (HUGS). National Hemophilia Foundation Annual Meeting, Dallas, TX, August 2015
53. Chen CX, Baker JR, Konkle BA, Ullman M, Kulkarni R, Hord J, Lou M, Nichol MB. BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS. ISTH 2015.
54. Chen C, Ullman M, Hord J, Kulkarni R, Konkle B, Baker J, Riske B, Koerper M, Wu J, Lou M, Nichol M. Characteristics Associated with Annual Bleeding Frequency Among Hemophilia Patients in the United States. International Society of Pharmacoeconomics and Outcomes Research European Congress, Milan, Italy. November 2015.
55. Barysaukas C, Bundy D, Gaur A, Winkle C, Miller M, Hord J, Werner E, Billett A. Burden of bloodstream infections among ambulatory pediatric hematology/oncology patients with a central line. 2016 ASCO Quality Care Symposium, Phoenix, AZ. February 2016.
56. Dandoy CE, Kelly T, Gaur A, Nagarajan R, Demmel K, Guinipero T, Savelli S, Hakim H, Aquino V, Chu R, Rae ML, Schjodt K, Huang F, Kilcrease T, Scurlock M, Marshburn A, Hill M, Castill J, Kaplan J, Adedeji R, Metz L, Powers R, Langevin M, Mitby P, Lee J, Youst A, Cooksey R, Mian A, Eckles S, Hord J, Billett AL . Outcomes of Pediatric Hematology/Oncology Inpatients that Develop A Bloodstream Infection. 2016 Annual Meeting of the American Society of Pediatric Hematology/Oncology, Minneapolis, MN. May 2016.
57. Wu J, Lou M, Gwadry-Sridhar F, Wasserman J, Riske B, Baker J, Hord J, Bradisse J, Konkle B, Kulkarni R, Ullman M, Koerper M, Curtis R, Niu X, Doctor J, Nichol MB. Comparison of Health Utilities in Persons with Hemophilia B. World Federation of Hemophilia Annual Meeting, Orlando, FL. July 2016.

*Denotes the presenter

TEACHING ACTIVITIES

Vanderbilt University School of Medicine-

Pediatric Grand Rounds-

Spring 1993	"Thrombocytopenia In Newborns and Older Children"
Spring 1994	"Clinical Applications of Colony Stimulating Factors"

Children's Hospital of Pittsburgh/University of Pittsburgh School of Medicine-

Medical Student Lectures-

Fall 1995	Pediatric Physical Diagnosis Course (MSII), Preceptor
Spring 1997	Integrated Case Studies Course (MSII), Facilitator
Spring 1998	Integrated Case Studies Course (MSII), Facilitator

July 1998	Mentor for Prematriculation student
Fall 1998	Pediatric Physical Diagnosis Course (MSII), Preceptor
November 1998	Integrated Life Sciences Course (MSIV)
	Sickle Cell Disease lecture and preceptor for 4 clinics
Spring 1999	Integrated Case Studies Course (MSII), Facilitator

Housestaff Lectures-

October 11, 1995	"Hematology/Oncology Emergencies"
March 14, 1996	"DIC and Coagulation Disorders"-Mercy
August 8, 1996	"Sickle Cell Disease: Pediatric Overview"-Mercy
December 4, 1996	"Sickle Cell Disease: A Review"
June 26, 1997	"Sickle Cell Disease in Adolescents"-Adol Med Noon Conf
August 13, 1997	"Sickle Cell Disease: A Review"
August 5, 1998	"Sickle Cell Disease: A Review"
July 21, 1999	"Sickle Cell Disease: Practical Guidelines"

Pediatric Grand Rounds

March 21, 1996	"Bleeding Diatheses in Children"
October 30, 1997	"Hypercoagulable Disorders and Thrombolytic Therapy in Children"
January 14, 1999	"Sickle Cell Disease: A Simple Substitution Leading To A Complex Disease"

Other CHP Conferences

September 27, 1997	Blood Disorders and Cancer in Childhood and Adolescence CME Symposium-"Bleeding Diatheses in Children"; "Sickle Cell Anemia Workshop"
June 27, 1998	New Advances in Sickle Cell Disease: A Conference for Patients and Families - Moderator for "Success Strategies Panel" and "Pediatric Pain Management" workshop

Children's Hospital Medical Center of Akron-

Housestaff Lectures

July 20, 2000	"Oncologic Emergencies"
August 10, 2000	"Hemoglobinopathies and Thalassemia"
February 14, 2001	"Bleeding Diatheses in Children"
November 20, 2001	"Hemoglobinopathies and Thalassemias"
January 24, 2002	"Peripheral Blood Smear Interpretations"
February 4, 2002	"Nelson Review- Blood Part I"
February 11, 2002	"Nelson Review- Blood Part II"
February 27, 2002	ED Fellows Conf- "Sickle Cell Emergencies"
February 20, 2003	"Bleeding Diatheses in Children"
April 8, 2003	"Hemoglobinopathies and Thalassemia"

May 15, 2003	“Evaluation of Anemia in Infants and Children”
July 24, 2003	“Aplastic Anemia”/”Controversies in ITP Management”
June 7, 2004	“Bleeding Diatheses in Children”
September 9, 2004	“Hemoglobinopathies and Thalassemia”
December 15, 2005	“Bleeding and Clotting Disorders in Children”
April 24, 2006	“Hemoglobinopathies and Thalassemia”
May 15, 2006-	“Anemias of Childhood”
December 3, 2007	“Thalassemias and Hemoglobinopathies”
May 30, 2008	“Anemia and Hemoglobinopathies- Board Review”
January 12, 2009	“Thalassemias and Hemoglobinopathies”
June 11, 2009	“Anemia and Hemoglobinopathies- Board Review”
June 14, 2010	“Thalassemias and Hemoglobinopathies”

Fellow Hem/Onc Core Lectures

August 13, 2007	“Sickle Cell Disease”
September 10, 2007	“Oncology Supportive Care”
February 25, 2008	“Neonatal Hematology”
July 25, 2008	“Marrow Failure and MDS”
December 1, 2008	“Hemolytic Anemias- Acquired and Inherited”
February 10, 2009	“Sickle Cell Disease”
March 10, 2009	“Oncology Supportive Care”
June 9, 2009	“The Day One Talk”
August 11, 2009	“Neonatal Hematology”
October 27, 2009	“Inherited Bleeding Disorders”
May 4, 2010	“Hemolytic Anemias- Acquired and Inherited”
August 3, 2010	“The Day One Talk”
August 24, 2010	“Sickle Cell Disease”
March 1, 2011	“Oncology Supportive Care”
July 12, 2011	“The Day One Talk”
August 9, 2011	“Inherited Bleeding Disorders”
November 8, 2011	“Oncology Supportive Care”
January 10, 2012	“Hemolytic Anemias- Acquired and Inherited”
March 6, 2012	“Practice Management”
October 30, 2012	“Neonatal Hematology”
March 26, 2013	“Bone Marrow Failure & MDS”
June 4, 2013	“Hem/Onc Practice Management”
September 23, 2014	“Bone Marrow Failure & MDS”
November 10, 2015	“Neonatal Hematology”
February 14, 2017	“Bone Marrow Failure & MDS”
June 13, 2017	“Oncology Supportive Care”

Fellows’ Research Seminar-

December 15, 2009	“Study Designs: Experimental Clinical Trials”
January 18, 2011	“Study Designs: Experimental Clinical Trials”
March 29, 2011	“Practice Management”
October 18, 2011	“Study Designs: Experimental Clinical Trials”

September 18, 2012 “Study Designs: Experimental Clinical Trials”

NEOUCOM Lectures

September 8, 2004 “ALL” (M2-POMS course)
 September 9, 2005 “ALL” (M2-POMS course)
 October 20, 2006 “ALL” (M2-POMS course)
 November 7, 2007 “Thalassemias and Hemoglobinopathies” (M2-POMS course)
 November 17, 2008 “Thalassemias and Hemoglobinopathies” (M2-POMS course)
 November 16, 2009 “Thalassemias and Hemoglobinopathies” (M2-POMS course)
 November 15, 2010 “Thalassemias and Hemoglobinopathies” (M2-POMS course)
 November 10, 2011 “Thalassemias and Hemoglobinopathies” (M2-POMS course)

Pediatric Grand Rounds

October 29, 1999 “Sickle Cell Disease: A Simple Substitution Leading To A Complex Disease”
 January 5, 2001 “Current Treatment for Acquired Aplastic Anemia in Children”
 March 19, 2004 Morbidity & Mortality joint presentation- “Pulmonary Emboli”
 April 16, 2004 “Childhood Cancer Update”
 July 29, 2005 Morbidity & Mortality joint presentation- “Spinal Cord Compression by Neuroblastoma in an Infant”
 January 18, 2008 Morbidity & Mortality presentation- “TTP”
 December 11, 2009 “Sudden Death of Athletes with Sickle Cell Trait- Is it Exertional Sickling?” (co-presenter along with Dr. Joe Congeni)
 April 20, 2012 “Understanding Maintenance of Certification”

Other CHMCA Conferences

August 11, 2000 Amish Health Fair, Millersburg, Ohio
 “Hot Topics for Those With Clotting Factor Deficiencies”
 February 20, 2001 City-wide ER Conference, CHMCA
 “Sickle Cell Emergencies”
 April 4, 2001 21st Annual Pediatric Update for the Practicing Physician “Three Common Reasons for a Hematology Referral”
 August 16, 2001 Amish Health Fair, Millersburg, Ohio
 “An Ounce of Prevention is Worth A Pound of Cure”
 September 26, 2001 “Hereditary Thrombophilias: Diagnosis and Management”
 Panelist, a CHMCA Seminar
 September 30, 2002 “Updates in Childhood Cancer... A Community Education Program” sponsored by CHMCA and Leuk/Lymph Society
 May 16, 2003 “Hemophilia Basics”, PEP Program, Cuyahoga Falls Sheraton
 August 8, 2003 Amish Health Fair, Millersburg, Ohio, “Hemophilia 101”
 April 20, 2004 Multicenter Pulmonology Videoconference - “Pulmonary Emboli”
 May 18, 2004 Trauma Multidisciplinary Case Review - “Hemophilia Basics”
 March 9, 2005 Participated in panel presentation “Getting the Right People on the Bus”, Goodyear Institute Leadership Network for Education
 August 4, 2005 Amish Health Fair, Millersburg, Ohio, “Prevention in

	Hemophilia” and “Financial Coverage for Pediatric Hemophilia Care”
August 11, 2005	NACHRI Oncology/Marrow Transplant Focus Group, “Overview of Oncology Services at Akron Children’s Hospital”
September 7, 2005	“Showers Center Overview”, Akron, OH
June 20, 2007	Ronald McDonald House of Akron Volunteer Seminar Community Healthcare Physician Group CME lecture, Green SummaYMCA, Green, OH
August 9, 2007	“Three Common Reasons for a Hematology Referral” Amish Health Fair, Millersburg, OH
April 1, 2009	29 th Annual Pediatric Update for the Practicing Physician “Evaluation of Anemia in the Child and Adolescent”
August 9, 2011	Amish Health Fair, Walnut Creek, OH “Recognizing and Treating Injuries and Bleeds”
October 19, 2011	“Childhood Cancer Update” ACH CME Dinner for Referring Physicians Austintown, OH
August 6, 2013	“Treatment for Hemophilia B and von Willebrand Disease” 2013 Amish and Mennonite Evening of Fellowship and Education Millersburg, OH
September 14, 2013	Salem Community Hospital Annual Pediatric Update “Abnormal White Blood Cell Counts- When to Worry” Salem, OH
October 4, 2017	Pediatric Palliative Care Curriculum- panel member “Compassion, Spirituality, and the Practice of Medicine”
March 14, 2018	Pediatric Bleeding Disorders Conference “Bleeding Disorders- Common Presentation and Approach to Diagnosis”, Akron, OH.

Other Outside Invited Lectures/Presentations-

December 1994	Pediatric Hematology Research Seminar, Univ Wisconsin “Hematopoietic CSF’s in the treatment of aplastic anemia.”
December 1994	Pediatric Hematology Research Seminar, Children's Hosp Buffalo “Hematopoietic CSF’s in the treatment of aplastic anemia”
April 26, 1996	Univ. Pitt Cancer Inst. Cont Ed Outreach Program, Warren, PA “Childhood Cancer: An Overview”
June 1, 1996	Pennsylvania Annual Sickle Cell Conference, Johnstown, PA “Overview of Pediatric Care”
November 2, 1996	Annual In-Service to Allegheny County (PA) School Nurses “Sickle Cell Disease”
May 17, 1997	Annual In-Service to Allegheny County (PA) School Nurses “Childhood Cancer: An Overview”
June 14, 1997	Annual Meeting of the Sickle Cell Programs of Pennsylvania

Plymouth Meeting, PA
 “Addressing Grievances in the Pediatric Setting”- panel member
 “Issues in Pediatric Treatment: Treatment and Prevention of Practice Issues In Sickle Cell Disease
 A Symposium sponsored by The Comprehensive Sickle Cell Center at C.H.O.P. held in Washington, DC
 “S. Pneumoniae Infection in Children with Sickle Cell Disease”

September 17, 1997

July 1998
 Mentor for Pennsylvania Governor’s School for Health Care student

August 19, 1998
 Pediatric Hematology Seminar
 Children’s Hospital, Columbus, Ohio
 “Practice Guidelines in the Treatment of Children with Sickle Cell Disease”

February 9, 1999
 Mercy Hospital Pediatric Grand Rounds, Pittsburgh, PA
 “Sickle Cell Disease: A Simple Substitution Leading To A Complex Disease”

February 23, 1999
 Hamot Family Medicine House staff Conference, Erie, PA
 “Practice Guidelines in the Treatment of Children with Sickle Cell Disease”

November 20, 1999
 Pediatric Blood and Marrow Transplantation Consortium Meeting
 Overview of Pediatric Aplastic Anemia Cooperative Trial (PAACT) studies- PAACT2 and PAACT3
 St. Louis, MO

February 9, 2000
 Barberton Citizen’s Hospital, Barberton, OH
 Medical Staff CME and FP Residency Lecture
 “Evaluation of Anemia in Infants and Children”

May 11, 2000
 St. Jude Children’s Research Hospital, Memphis, TN
 Hematology Grand Rounds
 “Current Therapy for Children with Acquired Aplastic Anemia”

May 18, 2000
 Ortho Biotech Pediatric Oncology Investigators Meeting, Dallas, TX
 “Procrit Therapy in Anemic Pediatric Cancer Patients”

September 16, 2000
 Annual Meeting of American Society of Pediatric Hematology/Oncology, Minneapolis, MN
 “Bone Marrow Failure Workshop”, Chair

April 27, 2001
 Annual Meeting of American Society of Pediatric Hematology/Oncology, Baltimore, MD
 “Bone Marrow Failure Workshop”, Chair

June 1, 2001
 Pediatric Research Seminar, Vanderbilt University, Nashville, TN
 “Current Therapy For Children With Acquired Aplastic Anemia”

July 28, 2001
 2001 Aplastic Anemia and MDS International Foundation Patient Conference, St. Louis, MO

- December 6, 2001 “Pediatric Treatment Options for Aplastic Anemia”
 “Pediatric Aplastic Anemia Cooperative Trials Update”
 Investigators Dinner supported by Wyeth-Ayerst
 Orlando, FL in conjunction with 2001 ASH Meeting
- April 11, 2002 Excessive Bleeding in Females: Could It Be VWD
 Sponsored by the N. Ohio Hemophilia FDN, Independence, OH
 “Treatment and Management of von Willebrand Disease”
- July 27, 2002 “Hemophilia 101”, FamOhio, Columbus, OH
- October 19, 2002 “Taking Care of Your Joints: The Role of Comprehensive Care,
 Prophylaxis, and Exercise”, Aurora, OH, Sponsored by Baxter
 AAP Practical Pediatrics CME Course
- November 8-10, 2002 Amelia Island, Florida
 “Sickle Cell Emergencies”, “Von Willebrand Disease: The Most
 Common Inherited Bleeding Disorder”, “Management
 Controversies in ITP”, “Evaluation of Childhood Anemia”
- April 23, 2003 AGMC Family Practice Resident Lecture, Akron, OH
 “Sickle Cell Disease: A Simple Substitution > Complex Disease”
- May 21, 2003 Ohio Univ. College of Osteopathic Med Pediatric Education Day
 “Sickle Cell Disease: A Simple Substitution > Complex Disease”
- February 16, 2005 ABleeding Diatheses in Children@, Columbus , OH
 126th Ohio General Assembly House/Senate Cancer Caucus
 “Childhood Cancer Overview@, Columbus, OH
- October 27, 2005 Children=s Oncology Group Cancer Control Meeting, Dallas, TX
 Double-blind, placebo-controlled trial of intravenous epoetin alfa
 in children with cancer receiving myelosuppressive chemotherapy.
- February 22, 2006 Akron General Health Report, Time-Warner Channel 23/Hudson
 Cable, Sickle Cell Disease
- April 30, 2006 ASPHO Practice Management Workshop, San Francisco, CA
 Results of the 2005 ASPHO Physician Compensation Survey
- May 17, 2006 Family Focus, Wadsworth Cable TV
 Sickle Cell Disease
- June 24, 2006 WAKR’s Akron General Good Health Radio Hour
 Sickle Cell Disease
- July 9, 2006 National Family/Patient/Physician Histiocytosis Conference
 Sydney Salem Golding Fund and Histiocytosis Assoc of America,
 Cleveland, OH
 “Clinical Presentation and Diagnosis of Childhood Langerhans
 Cell Histiocytosis”
- May 2, 2007 Pediatric Seminar, Union Hospital, Dover, OH
 “Three Common Reasons for a Hematology Referral”
- May 4, 2007 ASPHO Practice Management Workshop, Toronto, Canada
 “Pediatric Hematology/Oncology Practice of the Future”
- August 4, 2007 FamOhio, Columbus, OH

August 30, 2007	“Hemophilia 101” Joy in Our Town, WDLI Channel 17 (Canton TW Cable 7)
September 12, 2007	“Sickle Cell Disease and Trait” On Track with Betty Mac, Canton Cable System
September 15, 2007	“Sickle Cell and Childhood Cancer Awareness Month” Northern Ohio Hemophilia Foundation 53 rd Annual Meeting Cuyahoga Falls, OH
July 23, 2008	Expert panelist, “Straight Talk about Products and Services” Family Focus, Wadsworth Cable TV, Sickle Cell Disease
September 10, 2008	“Sickle Cell Disease and the Transition from Adolescence to Adulthood”, Summa Health System Internal Medicine Grand Rounds, Akron, OH
December 3, 2008	Grand Round Conference, Medina General Hospital, Medina, OH “Three Common Reasons for a Hematology Referral”
March 1, 2009	Community Profile, WAKR Radio Interview “Advances in the Treatment of Sickle Cell Disease”
May 19, 2009	“The OB/GYN’s Role in Von Willebrand Disease Detection” Dinner presentation sponsored by CSL Behring Akron, OH
July 29, 2009	Columbus Public Schools Seminar for Coaches, Trainers, Athletic Directors, Columbus, OH “Sudden Death in Athletes with Sickle Cell Trait- Exertional Sickling”
August 27, 2009	Joy in Our Town, WDLI Channel 17 “Sickle Cell Disease and Trait”
November 21, 2009	Hemophilia and VWD Overview and Panel Discussion Amish Health Fair, Berlin, OH
June 2010	“The Student-Athlete and the Sickle Cell Trait” A NCAA education video http://web1.ncaa.org/web_video/health_and_safety/sickle_cell/sickleCell.html
July 30, 2010	ATHN Data Summit 2010, Chicago, IL Moderator- “Tracking Quality Performance”
October 21, 2010	“What is like to be a doctor?” Phi Delta Epsilon International Medical Fraternity Kent State University
February 4, 2011	“Childhood Cancer Update”, Hillcrest Hospital, Mayfield Heights, OH
April 16, 2011	ASPHO Quality Improvement Workshop, Small Group Leader 24 th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Baltimore, MD. April 2011.
January 4, 2012	Childhood Cancer Update, Northside Medical Center, Family Practice Residents and Students, Youngstown, OH
February 24, 2012	Pediatric Grand Rounds, MetroHealth, Cleveland, OH “Sickle Cell Disease and Trait in Children”

May 9, 2012	“The Pediatric Hematology/Oncology Workforce in America Today”, ASPHO Annual Meeting of Division Directors, New Orleans, LA
September 27, 2012	Visiting Lecturer, Cincinnati Children’s Medical Center “Pediatric Hematology/Oncology Quality Collaborative” “Sudden Death in Athletes with Sickle Cell Trait- Is There a Connection?”
February 19, 2014	“How To Become a Pediatric Oncologist” Kent State University, Kent, OH
April 7, 2014	Gelfand Memorial Lecture, Ohio University “Childhood Cancer Overview”
May 17, 2014	ASPHO Maintenance of Certification Learning Session Review of “Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia.” Chicago, IL.
October 18, 2014	“Hemophilia Overview”, Annual Meeting of the Northern Ohio Hemophilia Foundation. Independence, OH.
November 7, 2014	“Ensuring Data Quality”, American Thrombosis and Hemostasis Network Data Summit, Chicago, IL
March 11, 2015	“Survey of the Landscape- 5 Key Ways the Day to Day Practice/Life of Subspecialists are Changing.” AAP Subspecialty Summit. Schaumburg, IL. (Co-presenter with Leo Heitlinger, MD)
March 30, 2015	“How To Become a Pediatric Hematologist Oncologist” and “Childhood Cancer Overview” Heritage Osteopathic College of Medicine, Ohio University
March 31, 2015	“How To Become a Pediatric Hematologist Oncologist” Careers Pathway Biology Class Kent State University, Kent, OH
October 30, 2015	“Data Quality 2.0”, American Thrombosis and Hemostasis Network Data Summit, Chicago, IL
November 17, 2015	“2015 ASPHO Compensation Survey Preview Webinar”
January 29, 2016	“SPS Pediatric CLABSI Webinar”- Co-presenter
February 22, 2016	Overview of the Showers Family Center, Wooster Rotary
February 26, 2016	“Systems to Reward Faculty for Non-Clinical Accomplishments” Translational Research in Hem/Onc/BMT Seminar Series Nationwide Children’s Hospital, Columbus, OH
May 3-4, 2016	Solutions for Patient Safety National Learning Session, Denver, CO- facilitated 4 sessions- Currently 90% Reliable to the Bundle and Sustaining Results, CLABSI in Hem Onc, Beyond the Bundle- When the Bundle Isn’t Enough, Addressing the Muddy Points
April 28, 2017	Pediatric Hematology Oncology Workforce Workshop , Annual Meeting of the American Society of Pediatric Hematology Oncology, Montreal, Canada. April 2017
May 26, 2017	Hematology-Oncology CLABSI Break-Out, Solutions for Patient Safety National Learning Session, Dallas, TX.

October 20, 2017	“Ensuring Data Quality”, American Thrombosis and Hemostasis Network Data Summit, Chicago, IL
May 25, 2018	“HoQ: Hem/Onc CLABSI Trivia Quiz and Learning Session” Solutions for Patient Safety National Learning Session, Chicago, IL
September 6, 2018	The Pediatric Hematology Oncology Workforce and Practice Management Considerations. Cleveland Clinic Foundation Fellow Lecture, Cleveland, OH
May 2, 2019	Quality Improvement within Pediatric Hematology Oncology and BMT. Quality Improvement Special Interest Group. Annual Meeting of the American Society of Pediatric Hematology Oncology. New Orleans, LA.
February 29, 2020	The Collection and Analysis of Pediatric Hematology Oncology Workforce Data. AMSPDC Annual Meeting. Long Beach, CA.
March 5, 2020	Overview of the Showers Family Center, Ashland Lions Club, Ashland, OH

FELLOWS TRAINED

- Jean Tersak, M.D.- Pediatric Hematology/Oncology Fellow, Children’s Hospital of Pittsburgh, 1996-1999
 - Scholarly Oversight Committee member for ED fellow, Heather Holsenback- 2006-2008
 - Mustafa Moazam, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2007-2010
 - Haleema Saeed, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2010-2013
 - Daniel Pettee, D.O.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2011-2014
 - Aditya Sharma, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2013- 2016
 - Nicholas McGregor, D.O.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital 2014 - 2017
 - Megan Sampson, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital 2014 – 2017
 - Erin Wright, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2015- 2018
 - Vanisha Patel, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2016-2019
 - Matthew Henderson, M.D.- Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital 2017- 2020
 - Elizabeth Stephens, M.D., Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2018- Present
 - Nicholas Farris, M.D., Pediatric Hematology/Oncology Fellow, Akron Children’s Hospital, 2019- Present
 - Adviser to Pediatric Residents, Akron Children’s Hospital- Erin Cockrell, Anthony Audino
-

RESEARCH INTERESTS

Aplastic Anemia, Oncology Supportive Care, Hemophilia B, Practice Management, Quality Improvement